

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

LIQUIDIA TECHNOLOGIES, INC.,  
Petitioner,

v.

UNITED THERAPEUTICS CORPORATION,  
Patent Owner.

---

Case No. IPR2020-00769 - Patent No. 9,593,066  
Case No. IPR2020-00770 - Patent No. 9,604,901

---

**DECLARATION OF RODOLFO PINAL, PH.D.**

## TABLE OF CONTENTS

	Page
I. QUALIFICATIONS .....	1
II. SCOPE OF WORK .....	5
III. SUMMARY OF OPINIONS.....	6
IV. LEGAL PRINCIPLES.....	11
V. OVERVIEW OF THE CHALLENGED PATENTS .....	15
A. Claims of the '066 Patent.....	15
B. Claims of the '901 Patent.....	20
C. Prosecution Histories .....	21
1. The Examiner Already Considered All of Liquidia's Prior Art During Prosecution.....	21
2. Examiner Valenrod Considered the Full Record of the '393 IPR During Prosecution .....	29
3. The '393 IPR Final Written Decision is Not Material to the Patentability of the Challenged Patent Claims.....	31
VI. THE LEVEL OF ORDINARY SKILL IN THE ART .....	41
VII. CLAIM TERMS.....	49
A. Terms Construed by Liquidia .....	49
1. "Product" or "Pharmaceutical Product".....	50
2. "Pharmaceutical composition comprising treprostini".....	52
3. "A process comprising" and "the process comprising" .....	53
B. Additional Terms.....	54
1. Starting Batch and Pharmaceutical Batch .....	54
2. Stored, Storing, Storage .....	57
3. A Salt Treprostini .....	58
VIII. DR. WINKLER'S GROUNDS LACK CREDIBLE BASES, IGNORE CLAIM LIMITATIONS, AND MISCONSTRUE THE ASSERTED ART .....	59
A. Misguided Focus on General Syntheses of Treprostini.....	59
B. Lack of Support for Conclusions .....	65
1. Phares Does Not Render Obvious Claims 1-7 of the '066 Patent.....	67

2.	Phares Fails to Teach All Aspects of Claims 8-10 of the '066 Patent.....	109
3.	Moriarty and Phares Do Not Render Obvious Claims 1-10 of the '066 Patent.....	112
4.	Phares Does Not Render Obvious Claims 1-9 of the '901 Patent.....	117
5.	Moriarty and Phares Do Not Render Obvious Claims 1-9 of the '901 Patent.....	127
IX.	OBJECTIVE INDICIA OF NON-OBVIOUSNESS.....	136
X.	CONCLUDING STATEMENTS.....	137
XI.	APPENDIX – LIST OF EXHIBITS.....	138

I, Rodolfo Pinal, declare as follows:

**I. QUALIFICATIONS**

1. I am currently Associate Professor in the Department of Industrial and Physical Pharmacy at Purdue University, in West Lafayette, Indiana, where I have been teaching since 2003. I also serve as Director of the NSF-I/UCRC Purdue Dane O. Kildsig Center for Pharmaceutical Processing Research (CPPR), a position I have held since 2005. Since 2016, I have served as Director of Graduate Studies in the Department of Industrial and Physical Pharmacy at Purdue. I am also a member of the Faculty Senate at Purdue.

2. I received my Ph.D. from the University of Arizona in Pharmaceutical Sciences with a concentration in Physical Chemistry.

3. I have over 30 years of experience studying formulation science, specifically on aspects pertaining to formulations for pharmaceutical composition and pharmaceutical product development. My professional experience includes over thirteen years working in the pharmaceutical industry.

4. At Purdue, I teach at both the graduate and undergraduate levels, including courses in pharmaceutical sciences, pharmaceutical formulation, pharmaceutical excipients, pharmaceutical processing and manufacturing, as well as performance testing and methods of analysis in pharmaceutical systems.

5. My research at Purdue focuses on three main areas. One has to do with the characterization of pharmaceutical solids, including crystal polymorphs, solvates, hydrates, and amorphous systems. A second area consists of utilizing the findings from this first area to elucidate the effect of solid-state properties on the performance attributes of pharmaceutical dosage forms. The third area combines the findings from the other two areas with the focus of developing novel technologies and processes for the production of dosage forms. My research on practical applications applies the findings from the theoretical part of my research, in order to develop formulation approaches and processing/manufacturing methods for drugs deemed problematic due to their solid-state, as well as solution/dissolution properties.

6. Prior to joining academia, I gained over thirteen years of industry experience in pharmaceutical research and development as a scientist with Hoffman-La Roche. From 1990-1993, I served as a Research Associate and then as a Senior Scientist in the pre-formulation group. During this time, my work focused on the physiochemical characterization of new chemical entities (*i.e.*, drug candidates), including developing stability-indicating methods, stability screening of drug candidates, photodegradation and drug-excipient compatibility studies, and solubility/solubilization and partitioning studies.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.